Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

This study tests whether adding a drug called Revumenib to standard intensive chemotherapy improves outcomes for people newly diagnosed with acute myeloid leukemia (AML) that carries a specific genetic mutation called NPM1 — a common change that affects how certain blood cells grow. **You may be eligible if...** - You are newly diagnosed with AML (not previously treated) and are a candidate for intensive chemotherapy - Your leukemia has an NPM1 gene mutation - You are in good general health (ECOG ≤ 2, or ≤ 1 if over 65) - Your liver, kidneys, and heart function are adequate - You have a life expectancy of at least 3 months **You may NOT be eligible if...** - You have acute promyelocytic leukemia (a different subtype) - You have active central nervous system disease - Your heart's QT interval is prolonged on ECG - You have a stomach or gut condition that prevents you from absorbing oral medication Talk to your doctor to see if this trial is right for you.